☆ 4.8 Article

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

NATURE MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Endocrinology & Metabolism

Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1

Rola Hammoud et al.

Summary: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) have incretin activity and play important roles in regulating glucose and lipid metabolism beyond the pancreas. They also have effects on weight loss, atherosclerosis, cardiorenal protection, and other physiological processes. Understanding the mechanisms of GIP and GLP1 action can lead to the development of new treatments for obesity and type 2 diabetes mellitus.

NATURE REVIEWS ENDOCRINOLOGY (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

Carel W. le Roux et al.

Summary: The SURMOUNT development program aims to evaluate the effectiveness and safety of tirzepatide as a treatment for obesity. The program includes four global phase 3 trials, which have shown that once-weekly administration of tirzepatide can significantly reduce body weight.

OBESITY (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Tim Heise et al.

Summary: In this study, the effects of tirzepatide, semaglutide, and placebo on body weight and composition, appetite, and energy intake were evaluated. The results showed that tirzepatide can effectively reduce body weight and appetite compared to placebo and semaglutide.

DIABETES CARE (2023)

添加到收藏夹

Review Medicine, Research & Experimental

New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics

Ania M. Jastreboff et al.

Summary: Nearly half of Americans are projected to have obesity by 2030, highlighting the urgent need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are the first agents in a promising landscape of hormone-based obesity therapeutics. With the expanding knowledge of obesity's neurobiology, the combination or formulation of emerging entero-endocrine and endo-pancreatic agents with GLP-1 RAs heralds a new era in targeted and mechanism-based obesity treatment.

ANNUAL REVIEW OF MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

W. Timothy Garvey et al.

Summary: This study assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, for weight management in individuals with obesity and type 2 diabetes. The results showed that once-weekly tirzepatide treatment significantly reduced bodyweight and achieved clinically meaningful weight loss, with a safety profile comparable to other weight management therapies.

LANCET (2023)

添加到收藏夹

Review Nutrition & Dietetics

Satiety Associated with Calorie Restriction and Time-Restricted Feeding: Peripheral Hormones

Debra K. M. Tacad et al.

Summary: Time-restricted feeding and continuous calorie restriction have similar effects on gut peptides involved in satiety, but the former may reduce hunger. Current research is still lacking, and more evidence and studies are needed to draw definitive conclusions.

ADVANCES IN NUTRITION (2022)

添加到收藏夹

Editorial Material Endocrinology & Metabolism

What's preventing us from curbing the obesity crisis?

[Anonymous]

LANCET DIABETES & ENDOCRINOLOGY (2022)

添加到收藏夹

Article Surgery

Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity The SLEEVEPASS Randomized Clinical Trial

Paulina Salminen et al.

Summary: This study compared the long-term outcomes of laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB) at 10 years. The results showed that LRYGB resulted in greater weight loss compared to LSG. However, both procedures were effective in achieving sustainable weight loss. LSG was associated with a higher prevalence of gastroesophageal reflux symptoms, while the occurrence of Barrett esophagus was similar between the two procedures.

JAMA SURGERY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

W. Timothy Garvey et al.

Summary: Results from the STEP 5 trial show that semaglutide treatment leads to significant and sustained weight loss over 104 weeks compared to placebo, with more participants achieving a weight loss of >= 5% in the semaglutide group.

NATURE MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Tirzepatide Once Weekly for the Treatment of Obesity

Ania M. Jastreboff et al.

Summary: In this 72-week trial in participants with obesity, once-weekly doses of 5 mg, 10 mg, or 15 mg of tirzepatide provided substantial and sustained reductions in body weight, and improvements in cardiometabolic measures were also observed.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial

Thomas A. Wadden et al.

Summary: This study compared the effects of once-weekly subcutaneous semaglutide with placebo as an adjunct to intensive behavioral therapy and initial low-calorie diet for weight management in adults with overweight or obesity. The results showed that semaglutide led to significantly greater weight loss compared to placebo over 68 weeks, with a higher proportion of participants achieving weight loss goals. More research is needed to evaluate the long-term effectiveness of this treatment.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John P. H. Wilding et al.

Summary: The study demonstrates that for individuals with obesity, once-weekly use of 2.4 mg semaglutide in combination with lifestyle intervention can lead to sustained and clinically relevant weight loss, with significant improvements in cardiometabolic risk factors and physical functioning reported by participants.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

The association between weight stigma and mental health: A meta-analysis

Christine Emmer et al.

OBESITY REVIEWS (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial

Thomas A. Wadden et al.

OBESITY (2020)

添加到收藏夹

Article Medicine, General & Internal

Obesity in adults: a clinical practice guideline

Sean Wharton et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)

添加到收藏夹

Review Endocrinology & Metabolism

How May GIP Enhance the Therapeutic Efficacy of GLP-1?

Ricardo J. Samms et al.

TRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)

添加到收藏夹

Letter Nutrition & Dietetics

Metabolic adaptation: is it really an illusion?

Eric Ravussin et al.

AMERICAN JOURNAL OF CLINICAL NUTRITION (2020)

添加到收藏夹

Article Psychology, Multidisciplinary

Lifestyle Modification Approaches for the Treatment of Obesity in Adults

Thomas A. Wadden et al.

AMERICAN PSYCHOLOGIST (2020)

添加到收藏夹

Article Medicine, General & Internal

Maintenance of Lost Weight and Long-Term Management of Obesity

Kevin D. Hall et al.

MEDICAL CLINICS OF NORTH AMERICA (2018)

添加到收藏夹

Article Endocrinology & Metabolism

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coskun et al.

MOLECULAR METABOLISM (2018)

添加到收藏夹

Review Medicine, General & Internal

Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults US Preventive Services Task Force Recommendation Statement

Susan J. Curry et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Review Medicine, General & Internal

Mechanisms, Pathophysiology, and Management of Obesity

Steven B. Heymsfield et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Endocrinology & Metabolism

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY

W. Timothy Garvey et al.

ENDOCRINE PRACTICE (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Models of Energy Homeostasis in Response to Maintenance of Reduced Body Weight

Michael Rosenbaum et al.

OBESITY (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial

Edward W. Gregg et al.

LANCET DIABETES & ENDOCRINOLOGY (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Initial weight loss goals: have they changed and do they matter?

M. R. Lent et al.

OBESITY SCIENCE & PRACTICE (2016)

添加到收藏夹

Article Medicine, General & Internal

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Xavier Pi-Sunyer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Endocrinology & Metabolism

Pharmacologic Sex Hormones in Pregnancy in Relation to Offspring Obesity

Elizabeth T. Jensen et al.

OBESITY (2014)

添加到收藏夹

Editorial Material Medicine, General & Internal

GUIDELINES Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance

Heather Stegenga et al.

BMJ-BRITISH MEDICAL JOURNAL (2014)

添加到收藏夹

Article Endocrinology & Metabolism

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

T. A. Wadden et al.

INTERNATIONAL JOURNAL OF OBESITY (2013)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes

Rena Wing et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Endocrinology & Metabolism

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

Rena R. Wing et al.

DIABETES CARE (2011)

添加到收藏夹

Article Medicine, General & Internal

Long-Term Persistence of Hormonal Adaptations to Weight Loss

Priya Sumithran et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Medicine, General & Internal

Extended-Care Programs for Weight Management in Rural Communities The Treatment of Obesity in Underserved Rural Settings (TOURS) Randomized Trial

Michael G. Perri et al.

ARCHIVES OF INTERNAL MEDICINE (2008)

添加到收藏夹

Article Medicine, General & Internal

Comparison of strategies for sustaining weight loss - The weight loss maintenance randomized controlled trial

Laura P. Svetkey et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)

添加到收藏夹

Article Medicine, General & Internal

Effects of bariatric surgery on mortality in Swedish obese subjects

Lars Sjostrom et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

添加到收藏夹

Article Medicine, General & Internal

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin

WC Knowler et al.

NEW ENGLAND JOURNAL OF MEDICINE (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.